Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.
-
Clinical Benefit
Moderate
The actual benefit is moderate.
Clinical Added Value
minor
The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III.
Listen
